Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
about
Voriconazole therapeutic drug monitoring.Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveRecent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosisAspergillosis of bones and joints - a review from 2002 until today.Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column.Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS/MS.In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3Voriconazole pharmacokinetics in liver transplant recipients.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsVoriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosisVoriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosisCorrelation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Inflammation is associated with voriconazole trough concentrations.Cyclodextrins.Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Voriconazole: a new triazole antifungal agent.Human pharmacogenomic variations and their implications for antifungal efficacy.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Recommendations for the treatment of fungal pneumonias.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Influence of inflammation on voriconazole metabolismSystemic antifungal therapy: new options, new challenges.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Antifungal pharmacokinetics and pharmacodynamicsPharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsPharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.Pharmacokinetics of antifungal agents in children.
P2860
Q24542411-77DEA059-6856-4BCF-A3E4-3E0013A47D08Q27009221-8669C39C-8042-4DA9-8C91-97C187020E74Q28675835-7BFD378F-1092-455D-8D37-51C1453442CEQ30727401-E43782F3-5B61-41A7-973F-EF90B0FC330BQ30981299-D505B3D7-9A7D-480F-BBD0-1938EEDD39EDQ31115252-FACB4FB8-C0C4-4C4D-958E-2D00F8BFF386Q33392206-118D9566-0367-460E-8FB8-6610F263719EQ33448151-3107D5EC-6E24-4E13-8350-D0D7B4037467Q33574651-6887F33A-7CC3-42F9-955C-93A9AAD13FF9Q33613685-6BF34D86-C27B-4482-83B9-18455033BDE0Q33763177-02863501-10E6-4240-9F2B-A554BFBBEC64Q33774641-309240FE-D666-4369-BF25-365CE3512915Q33849298-5BC2A18A-828E-4303-BC71-E4CAC748C52FQ34020402-9877D4A4-922F-42EB-9560-38EF37640C69Q34045383-3D56FEFA-6A50-48FF-AFA0-BD93A161833FQ34058346-3FC57EBF-295F-45BB-827F-5ACB36AACED0Q34150923-D3C18BC8-1EB1-4B20-9637-CB54735B645CQ34290034-13C24D29-2323-410D-AC71-83660F32CBC3Q34431984-FAE7D5AF-A2F0-4D26-94E0-5E49A7B10416Q34596313-1F634615-086D-4ECF-B338-625510990D9FQ34597394-7A6B326E-61B1-45C8-8D68-548A4FCCDE8AQ34761190-1640E91E-5214-4A42-B4C8-CBE45235FC56Q35004898-E0C2AEEA-5DC9-4414-A1C7-CF56EA56FA2DQ35026481-C9FCCB75-786F-41AF-80BF-B23DD657B2FBQ35069136-A61C5C7B-A99F-4316-AF63-316A5F4B19D5Q35070838-EDBEF7B9-870B-4A6D-8686-A911C9148815Q35105949-851C7429-94E8-403E-8A81-CE553B5F8F18Q35183728-471E0ECB-770A-46A1-829E-2CC51FF8704DQ35270270-56D6B6D0-2140-403B-90BE-35E5BED64805Q35318531-A530B1D9-263A-4246-BE45-31CE7CC2CE88Q35364006-20DF5300-BD67-4748-89FF-172B5E60A619Q35386048-D9289DF8-DFF5-4212-82FD-74622A2C5FFAQ35585219-9D1DBE9E-9BFB-4C62-96EF-222E1DB26D46Q35598532-5F745AF1-D97E-4498-9FC3-806ED8DC2FAFQ35635830-71CE6444-C367-4549-B08E-ABB1E5071455Q35663841-A85402AB-CB4C-4797-BF3F-679B0995FE60Q35685548-3642A4B3-F7AE-4D0C-9E74-3993D3F22056Q35959476-DB14BC89-B29D-427F-8F90-5348ED7A1198Q36048229-2BFD40F0-EB1E-410D-A0B9-025695B46AA9Q36163345-1FFEB208-779F-47B0-85E8-18A0F0229F7F
P2860
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pharmacokinetics and safety of ...... oral-dose escalation regimens.
@en
Pharmacokinetics and safety of ...... oral-dose escalation regimens.
@nl
type
label
Pharmacokinetics and safety of ...... oral-dose escalation regimens.
@en
Pharmacokinetics and safety of ...... oral-dose escalation regimens.
@nl
prefLabel
Pharmacokinetics and safety of ...... oral-dose escalation regimens.
@en
Pharmacokinetics and safety of ...... oral-dose escalation regimens.
@nl
P2093
P2860
P1476
Pharmacokinetics and safety of ...... oral-dose escalation regimens.
@en
P2093
Ghahramani P
Greenhalgh K
Kleinermans D
P2860
P304
P356
10.1128/AAC.46.8.2546-2553.2002
P407
P577
2002-08-01T00:00:00Z